Why Ozempic Causes Nausea: The Biology Behind Semaglutide's Most Common Side Effect

How common is nausea on Ozempic?

Nausea is the most frequently reported adverse reaction to Ozempic. The label lists it, with vomiting, diarrhea, abdominal pain and constipation, among the reactions seen in at least 5% of treated patients [1]. In the two placebo-controlled trials pooled in the label (521 people exposed to Ozempic, mean 32.9 weeks), nausea occurred in 6.1% of the placebo group, 15.8% of the 0.5 mg group and 20.3% of the 1 mg group [1]. Vomiting ran 2.3%, 5% and 9.2% across those groups, and diarrhea 1.9%, 8.5% and 8.8% [1].

Counting all gastrointestinal reactions together, the rates were 15.3% on placebo, 32.7% on 0.5 mg and 36.4% on 1 mg, and treatment was stopped for a GI reason by 0.4%, 3.1% and 3.8% respectively [1]. Severe GI reactions were reported by 0.4% on 0.5 mg and 0.8% on 1 mg, against 0% on placebo [1].

The 2 mg dose was compared with 1 mg in a 40-week trial of 959 patients: GI reactions occurred in 34% on 2 mg and 30.8% on 1 mg, and no new safety signals were identified [1].

What delayed gastric emptying actually looks like

The Ozempic label says the drug causes a delay in gastric emptying and can affect how oral medicines are absorbed; in clinical pharmacology trials, semaglutide did not change the absorption of oral medicines to a clinically relevant degree [1].

The clearest measurement of the effect comes from a crossover trial in which adults with obesity received once-weekly semaglutide, escalated to 1 mg, or placebo for 12 weeks each [3]. In that study of 30 adults, a paracetamol absorption test indicated slower gastric emptying during the first hour after a meal (ratio 0.73, 95% CI 0.61 to 0.87) [3]. Overall emptying across five hours was not statistically different from placebo [3].

Does semaglutide act on the brain's vomiting center?

The area postrema is located on the dorsal surface of the medulla oblongata at the caudal end of the fourth ventricle. It is a circumventricular organ that lacks a specific blood-brain diffusion barrier to large polar molecules, so it is positioned to detect emetic toxins in the blood and cerebrospinal fluid. It has been implicated as a chemoreceptor trigger zone for vomiting for over 40 years: lesions of the area postrema prevent vomiting in response to most, but not all, emetic drugs, though it is not essential for vomiting induced by motion or by activation of vagal nerve afferents [4]. Activation of the area postrema probably leads to nausea and vomiting through its projection to the neighboring nucleus of the solitary tract [4].

Semaglutide activates GLP-1 receptors, and those receptors are present in brain regions that regulate food intake, including hypothalamic nuclei and hindbrain nuclei such as the nucleus of the solitary tract [2][1]. Long-acting GLP-1 analogues given peripherally reduce food intake largely through humoral pathways acting directly on brain GLP-1 receptors [2].

The evidence on these brain pathways comes from a review of neural circuitry and animal work [2]; the human data on nausea are the trial rates and their relationship to dose [1].

In the ventral tegmental area, nucleus accumbens and ventral hippocampus, GLP-1 receptor activation reduces food intake and body weight without concomitant nausea responses, which the review says may make those pathways of interest for future obesity drugs [2].

Why nausea clusters around dose increases

The Ozempic label says the majority of reports of nausea, vomiting and diarrhea occurred during dose escalation [1]. The schedule it describes moves in four-week steps: 0.25 mg weekly for four weeks (not a maintenance dose), then 0.5 mg, then 1 mg and up to 2 mg, with each increase after at least four weeks on the current dose [1].

The Rybelsus and Ozempic tablets label says to follow its starting and escalation schedule to reduce the risk of gastrointestinal adverse reactions [5]. In the injection label's trials the rates were higher at the larger doses: nausea was reported in 15.8% at 0.5 mg and 20.3% at 1 mg, and gastrointestinal reactions in 30.8% at 1 mg and 34% at 2 mg [1].

When nausea is more than nausea

The label treats GI reactions as an adverse event class that can be severe, and says Ozempic is not recommended in people with severe gastroparesis [1]. Postmarketing reports in the Ozempic label include ileus, intestinal obstruction and severe constipation with fecal impaction [1].

The label's kidney warning concerns acute kidney injury, in some cases requiring hemodialysis, reported mostly in people whose GI reactions such as nausea, vomiting or diarrhea led to dehydration; the label advises monitoring renal function in people with reactions that could cause volume depletion, especially during initiation and escalation [1].

Acute pancreatitis is on the label as a serious risk, with persistent or severe abdominal pain sometimes radiating to the back, which may or may not be accompanied by nausea or vomiting; the label says to discontinue Ozempic if pancreatitis is suspected [1].